Penn Memory Center

Last week, Penn Memory Center Co-Director Jason Karlawish, MD, joined clinicians, advocates, and people with lived experience for a Capitol Hill briefing on “What Early Detection Means for Alzheimer’s Patients and Providers.”

The discussion focused on why early detection matters for individuals living with Alzheimer’s disease and their families. Earlier diagnosis can help people better understand their symptoms, consider treatment and care options, and plan for the future.

The briefing also highlighted two pieces of legislation: the Alzheimer’s Screening and Prevention Act and the BRIDGE for Young-Onset Alzheimer’s Disease Act of 2025. Both speak to a larger need: building systems that help people access diagnosis, care, and support earlier.

What happens when a major review reaches a different conclusion than many clinicians and researchers in the field?

A recent Cochrane review found that amyloid-targeting treatments for Alzheimer's disease produce little cognitive benefit while increasing the risk of adverse effects. The publication has prompted discussion about how evidence should be evaluated and communicated.

In a new episode of the Dementia Matters podcast by the Wisconsin Alzheimer's Disease Research Center, Penn Memory Center co-director Dr. David Wolk joins Dr. Cynthia Carlsson and Dr. Henrik Zetterberg to unpack the review and discuss what it means for patients, clinical care, research, and public policy.

Addressing Cochrane’s Review on Amyloid-Targeting Treatments for Alzheimer’s Disease | Alzheimer's Disease Research Center Amyloid-targeting monoclonal antibody treatments have ushered in a new era of Alzheimer’s disease therapies after decades of research and clinical trials. A recent review published by Cochrane, a global, independent, non-profit network of researchers, professionals, patients and carers regarded as...